Holen Sie sich die Stockscreener-App
3.18
4.93%
-0.165
Handel nachbörslich:
3.18
Schlusskurs vom Vortag:
$3.345
Offen:
$3.37
24-Stunden-Volumen:
2.06M
Relative Volume:
1.40
Marktkapitalisierung:
$386.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-217.44M
KGV:
-1.7202
EPS:
-1.8486
Netto-Cashflow:
$-205.20M
1W Leistung:
-27.56%
1M Leistung:
-27.40%
6M Leistung:
-55.08%
1J Leistung:
-51.82%
1-Tages-Spanne:
$3.145
$3.385
1-Wochen-Bereich:
$3.145
$4.49
52-Wochen-Spanne:
$3.145
$9.86
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Vergleichen Sie PRME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| PRME | 3.18 | 386.50M | 0 | -217.44M | -205.20M | -1.8486 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
FY2024 EPS Forecast for Prime Medicine Increased by Analyst - Defense World
FY2024 EPS Estimates for Prime Medicine Reduced by Analyst - Defense World
Wedbush Forecasts Prime Medicine FY2024 Earnings - Defense World
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Prime Medicine (NYSE:PRME) Raised to Sell at StockNews.com - Defense World
Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace
FY2024 EPS Estimate for Prime Medicine Decreased by Analyst - MarketBeat
Chardan Capital Issues Pessimistic Forecast for Prime Medicine (NYSE:PRME) Stock Price - Defense World
Prime Medicine (NYSE:PRME) Earns “Buy” Rating from HC Wainwright - Defense World
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Prime Medicine Reports Q3 2024 Financial Progress - TipRanks
Prime Medicine's (PRME) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
FMR LLC Bolsters Stake in Prime Medicine Inc - GuruFocus.com
Prime Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
ARK Investment Management LLC Lowers Stock Position in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Head to Head Review: Prime Medicine (NYSE:PRME) and Invivyd (NASDAQ:IVVD) - Defense World
Prime Medicine (NYSE:PRME) Receives Buy Rating from HC Wainwright - MarketBeat
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.50 - Defense World
Prime Medicine Presents In Vivo Proof-of-Concept Data - GlobeNewswire
Prime Medicine Advances Gene Editing for Liver Diseases - TipRanks
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress - Yahoo Finance
Deals In Depth: September 2024 - Citeline News & Insights
Prime Medicine (NYSE:PRME) Shares Down 4.6%Should You Sell? - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Up 15%What's Next? - MarketBeat
Why I Keep Buying These 14 Incredible Growth Stocks - The Motley Fool
There is no doubt that Prime Medicine Inc (PRME) ticks all the boxes. - SETE News
Prime Medicine to Highlight New Preclinical Data, Including - GlobeNewswire
Market Watch Highlights: Prime Medicine Inc (PRME) Ends on an Upturn Note at 3.73 - The Dwinnex
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings - Yahoo Finance
Prime Medicine Inc (PRME) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Prime Medicine, Inc. (NYSE:PRME) Shares Purchased by Millennium Management LLC - MarketBeat
The Significance of Moving Averages in Prime Medicine Inc Inc. (PRME) Price Performance - The InvestChronicle
Check out these key findings about Prime Medicine Inc (PRME) - SETE News
Prime Medicine Inc [PRME] Investment Guide: What You Need to Know - Knox Daily
Prime Medicine lays off workers as it trims pipeline - STAT
Insider’s View: Deciphering Prime Medicine Inc (PRME)’s Financial Health Through Ratios - The Dwinnex
News: CMN Weekly (4 October 2024)Your Weekly CRISPR Medicine News - CRISPR Medicine News
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday - MSN
A new trading data show Prime Medicine Inc (PRME) is showing positive returns. - SETE News
Prime Medicine Inc (PRME) rating initates by H.C. Wainwright - Knox Daily
Prime Medicine, Inc. Expected to Earn Q4 2024 Earnings of ($0.28) Per Share (NYSE:PRME) - Defense World
Prime Medicine (NYSE:PRME) Given "Buy" Rating at HC Wainwright - MarketBeat
Prime Medicine’s (PRME) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Q4 2024 EPS Estimates for Prime Medicine, Inc. (NYSE:PRME) Lifted by Wedbush - MarketBeat
PRME Stock Rises 11.8% on Collaboration With Bristol Myers - Zacks Investment Research
BMS Inserts Cash Into Prime Medicine’s Gene-Editing Ambitions - Scrip
BMS and Prime ink potential $3.5bn deal to develop T cell therapies - Yahoo Finance
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):